COCP

Over the past six months, Cocrystal Pharma's stock has been impacted by several events. In December 2025, the company received Institutional Review Board approval from Emory University School of Medicine to conduct a Phase 1b human challenge study for CDI-988. On March 9, 2026, the first subjects were dosed in its Phase 1b study evaluating CDI-988 for norovirus prevention and treatment. On March 31, 2026, Cocrystal Pharma reported its 2025 financial results and provided updates on its antiviral drug-development programs. On April 2, 2026, the company received FDA Fast Track Designation for CDI-988 for norovirus infection treatment and prevention, leading to a significant positive market reaction. On the same day, a new major risk was identified regarding the company's financial position, indicating less than a year of cash runway. On April 30, 2026, Cocrystal Pharma presented at the 39th International Conference on Antiviral Research (ICAR 2026), highlighting the mechanism of action and clinical advancement of CDI-988. On May 1, 2026, a board change was noted, with an observation of insufficient new directors.